VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
SPRY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
SPRYARS Pharmaceuticals, Inc.
$3.69$366M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
SPRY logo

ARS Pharmaceuticals, Inc.

SPRY
NASDAQ · Immunology Biotech
$3.69
At close - Nov 18, 4:00 PM EST - USD
Market Cap$366M
P/E-1.8x
52W High$13.15
Volume1.7M
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Volatile Revenue and SG&A Overhang Strain Liquidity

ARS Pharmaceuticals' investment thesis is centered on the uncertain commercial trajectory of its product, which has generated erratic quarterly revenue ranging from $2.1M to $86.6M over the past year.

GrowthMixed
ProfitabilityStrained
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

SPRY price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

2/12 Beats

EPS beat 2 of last 12 quarters

02

Valuation risk

-106% Peers

P/E is 106% below peer median

03

Market leadership

RS 17 · Lag

Laggard (Underperforming 83% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
SPRY-67.89%
S&P 500 (^GSPC)+6.88%
1-Year Return
SPRY-47.95%
S&P 500 (^GSPC)+10.62%
3-Year Return
SPRY-22.80%
S&P 500 (^GSPC)+60.26%
5-Year Return
SPRY-54.56%
S&P 500 (^GSPC)+62.56%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y Low
-1.8x
Forward P/E
N/A
EV/EBITDA
N/A
FCF YieldCash Flow
N/A

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
-1.8x
135.1x
0th· Low
EV/EBITDA
N/A
N/A
N/A
Price/FCF
N/A
83.2x
N/A
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
No DCF Model AvailableIntrinsic value modeling is not supported for this equity.

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$84M-5.5% YoY
Net income FY25
-$171M-2241.8% YoY
Free cash flow FY25
-$171M-1418.5% YoY
Operating margin FY25
-212.9%-209.5 pts YoY
ROIC (FY25)-71.7%
Avg ROIC 5Y-39.5%
ROE (TTM)-453.9%
Piotroski Score3 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate2/12 (17%)
Revenue Beat Rate5/12 (50%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
-$0.36-18.0%
vs -$0.30
$38M-10.2%
vs $42M
Q3 2026
Aug 13, 2026
-$0.63-31.9%
vs -$0.48
$34M+7.5%
vs $31M
Q2 2026
May 15, 2026
-$0.61-15.1%
vs -$0.53
$23M+2.2%
vs $22M
Q2 2026
Mar 9, 2026
-$0.42+0.0%
vs -$0.42
$28M+9.7%
vs $26M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Defense World·Nov 9, 2026
CenterBook Partners LP Buys 295,532 Shares of ARS Pharmaceuticals, Inc. $SPRY

CenterBook Partners LP raised its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) by 239.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 419,156 shares of the company's stock after buying an additional 295,532 shares during the period.

Benzinga·Nov 6, 2026
ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results

ARS Pharmaceuticals (NASDAQ:SPRY) on Thursday reported weaker-than-expected results for the third quarter.

Seeking Alpha·Nov 6, 2026
ARS Pharmaceuticals, Inc. (SPRY) Q3 2026 Earnings Call Transcript

ARS Pharmaceuticals, Inc. ( SPRY ) Q3 2026 Earnings Call November 5, 2026 4:30 PM EST Company Participants Donn Casale - CEO, President & Director Meg Smith Kathleen Scott - Chief Financial Officer Conference Call Participants Monique Allaire - Thrust Strategic Communications Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Frank Wang Zhong - Leerink Partners LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Presentation Operator Good afternoon, and welcome to ARS Pharma's Third Quarter 2026 Earnings Conference Call.

MarketBeat·Nov 6, 2026
ARS Pharmaceuticals Q3 Earnings Call Highlights

ARS Pharmaceuticals NASDAQ: SPRY reported $33.4 million in third-quarter U.S. net product revenue from its needle-free epinephrine treatment neffy and reaffirmed its goal of reaching cash flow breakeven by the end of 2027.

Filtered for ARS Pharmaceuticals, Inc.More Headlines
04

Compare before deciding

Benchmark SPRY against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for ARS Pharmaceuticals, Inc. (SPRY)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
SPRY logoSPRYARS Pharmaceuticals, Inc.Current
$3.69$366.43M-1.84-5.46%-163.64%-453.93%—
ADMA logoADMAADMA Biologics, Inc.
$13.56$3.14B16.7919.63%35.14%42.56%—
PRAX logoPRAXPraxis Precision Medicines, Inc.
$305.19$8.51B-24.78-100%—-29.41%—
NTRA logoNTRANatera, Inc.
$289.50$41.46B-253.2135.9%-5.66%-9.18%—
TLRY logoTLRYTilray Brands, Inc.
$2.25$300.02M-1.8311.46%-17.05%-9.54%—
HALO logoHALOHalozyme Therapeutics, Inc.
$95.80$11.36B24.2037.55%26.93%544.26%—

Compare SPRY vs Peers

ARS Pharmaceuticals, Inc. (SPRY) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ADMA

Most directly comparable listed peer for SPRY.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare SPRY against a more recognizable public peer.

Peer Set

Compare Top 5

vs ADMA, PRAX, NTRA, TLRY

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

SPRY SEC Filings & Documents

ARS Pharmaceuticals, Inc. (SPRY) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 13, 2026·SEC

Material company update

Jul 17, 2026·SEC

Material company update

Jul 7, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 9, 2026·SEC

FY 2025

Mar 20, 2025·SEC

FY 2024

Mar 21, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 13, 2026·SEC

FY 2026

May 15, 2026·SEC

FY 2025

Nov 10, 2025·SEC

Get notified when SPRY posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

SPRY Frequently Asked Questions

ARS Pharmaceuticals, Inc. (SPRY) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is ARS Pharmaceuticals, Inc.'s revenue?

ARS Pharmaceuticals, Inc. (SPRY) reported $122.1M in revenue over the trailing twelve months. Revenue was $84.3M in fiscal year 2025.

How fast is ARS Pharmaceuticals, Inc. growing?

ARS Pharmaceuticals, Inc. (SPRY) revenue fell by 14.5% over the trailing twelve months, compared with the twelve months before.

Is SPRY profitable?

No. ARS Pharmaceuticals, Inc. (SPRY) reported a net loss of $199.9M over the trailing twelve months.

Dividend & Returns
What is SPRY's return on equity?

ARS Pharmaceuticals, Inc. (SPRY) had a return on equity (ROE) of -453.9% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is ARS Pharmaceuticals, Inc.'s free cash flow?

ARS Pharmaceuticals, Inc. (SPRY) had negative free cash flow of $183.1M over the trailing twelve months.

What if you invested $1,000 in SPRY back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →